Key Takeaways
- Profit-led quarter, capacity-constrained top line: Net profit grew 12.38%, outpacing 9.84% total income growth, while H1 revenue growth of only 10% reflects the old facility running at 124–128% of capacity with no contribution yet from the new YEIDA plant.
- The new facility is the entire story: Trial production began September 2026, commercial readiness awaits only final statutory certificates, and management is under "tremendous pressure" from customers to start supplies, making the ramp-up pace the singular driver of near-term performance.
- FY29 ₹300 crores target reaffirmed: Management stands by the earlier projection and believes in giving conservative figures, having "always performed better than what we have committed."
- Margins held up under strain: Gross margin improved on operational efficiency and maximum utilization; depreciation rose only 20% despite a 3.5x capacity increase, though higher depreciation looms once the new facility starts commercial production.
- What to watch next quarter: Whether final statutory certificates arrive and commercial production begins, the initial pace of the YEIDA ramp-up, and the first quantification of the new facility's depreciation impact.
The YEIDA Facility: The Quarter's Only Material Event
- Status: Installation and commissioning completed during H1 FY27; trial production commenced September 2026; all necessary inspections completed; awaiting issuance of final statutory certificates before formally commencing commercial production and supplies.
- Readiness: Substantial orders and necessary raw materials are already available to support commencement; robotic production and complete setup are operational and visitable.
- Customer pull: Management stated they are "under tremendous pressure from our customers to commence the supplies," with the old facility already operating 28% above rated capacity, creating an acute supply bottleneck that the new plant must relieve.
- Remaining spend: Some amounts yet to be paid as per contractual terms with different vendors; other departments at the facility will take some time, but the production facility itself is ready.
- IPO proceeds fully deployed: All IPO proceeds have been deployed towards the YEIDA facility, supplemented by a ₹60 crores loan from HDFC.
- Future headroom: The facility occupies only half of the 21,250 sqm plot; management will not commit to specifics but stated "we will continue to do our best and we are not there to stop."
Manoj Arora: "already we are doing at 28% higher than our capacity, okay? And we are under tremendous pressure. You can very well visualize where we are going, okay? And how soon we can bring this new facility to the maximum possible level of utilization."
Growth Drivers & Demand Environment
- Structural tailwinds: Clients are launching many more new products than before (multiplied from roughly 10 per year earlier); new-generation consumers are saving less and spending more on food and non-food consumer products; products that were once luxuries are now necessities.
- Industry backdrop: B2C beauty brands are performing very well; fragrance and flavour are integral to end-product identity; Indian FMCG is growing exponentially, with buying power rising fast.
- Customer stickiness: Fragrance and flavours is a very sticky business; products do not get changed often unless there is a change in quality or regulations; existing customers provide continuity and year-on-year growth.
- Southern India strength: The company is very strong and active in southern India, working with both pan-India and regional players where many customers have a strong presence.
- Both segments firing: Fragrances (non-food FMCG) and flavours (food FMCG) are both growing very fast; the company will strive to perform in both.
- Competitive position: Management sees itself as a small player in a very large industry, having "not even touched the tip of the iceberg," and views competition as motivation rather than a threat.
Manoj Arora: "It took me decades to convince customers that India can produce. Look at the growth story of India. India has started growing very fast in last -- some time. So, we are also the part of the growth journey."
Margins, Costs & the Depreciation Overhang
- Gross margin improvement: Achieved through operational efficiency and operating at maximum utilization of capacity; the industry environment was also supportive.
- Depreciation lag: Depreciation rose only 20% despite capacity increasing 3.5x because the new facility is not yet in commercial production; higher depreciation is expected in future, but management argues it will not have a "very big impact" because turnover is increasing very fast.
- Margin confidence: Management sees no reason margins cannot be maintained and no challenge expected on profit margins despite customer pressure; the company commits to trying to maintain EBITDA and is "very, very conscious" about investor returns.
- Depreciation quantification avoided: An analyst asked for a range on expected H2 depreciation; management declined, stating it depends on the day production starts and offered to share exact numbers later by email.
- IFRA 52nd Amendment: Upcoming in January 2027; the company is already preparing and making submissions to customers, treating regulatory compliance as routine and stating it complies with all global guidelines "in TOTO."
Manoj Arora: "it is a part of our lives, okay? Part of the game. And it is, better safety guidelines, better and the best thing is that we are a company which complies with all these guidelines in TOTO."
Capacity, Utilization & the Ramp-Up Question
- Current strain: The existing facility is operating significantly above rated capacity (stated as both 28% and 20% higher on different pages), creating pressure to ramp up the new facility quickly.
- Ramp-up expectations: Management expects the ramp-up to happen "very, very fast" due to tremendous customer pressure and existing over-capacity operations, but makes no specific commitment on timeline, using phrases like "earliest possible" and "very soon" repeatedly.
- Demand quantification avoided: An analyst asked what percentage of the additional YEIDA capacity is already supported by confirmed customer demand versus needing new orders; management declined to quantify, stating "it will be very hard to quantify this in a percentage."
- Asset-turn question deflected: An analyst asked what asset turn is expected from the new facility specifically; management referred to the combined Sacheerome projection of ₹300 crores for FY29 and did not provide a facility-specific figure or confirm the analyst's computed 1.5–2x range.
Dhruv Arora: "Our investments in the YEIDA facility, they are aimed at supporting our long-term capacity expansion and business growth. So, while the addition of these assets may initially morbid the asset turnover ratio, but the facility is designed to provide sustainable manufacturing capabilities to us and support our future business requirements."
Related-Party & Governance Items
- Sachee Fragrances & Chemicals Private Limited: Confirmed as completely separate, separated more than 27 years ago, with no transactions and different businesses.
- Divcare PC&H: 98% owned by Manoj Arora's daughter, 2% by wife Alka Arora; Manoj Arora stated he has nothing to do with that business.
- Industry specialization: The company highlighted the rarity of its expertise, noting "it's a widely quoted fact that there are more astronauts in the world than perfumers."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Commercial production start | YEIDA facility to commence commercial production and supplies upon receiving final statutory certificates | Awaiting certificates; no date given |
| FY29 revenue target | ₹300 crores consolidated revenue | FY29 |
| Capex plan | No change; everything fully as per planning | Ongoing |
| EBITDA maintenance | Management commits to maintaining EBITDA; "very, very conscious" of investor returns | Ongoing |
| IFRA 52nd Amendment compliance | Already preparing and making submissions to customers | By January 2027 effective date |
| Depreciation details | Exact numbers to be shared later by email, calculated from the day production starts | After production start date is known |
Key Metrics
| Metric | H1 FY27 |
|---|---|
| Total income | ₹85.92 cr, +9.84% YoY from ₹78.22 cr in H1 FY26 |
| EBITDA | ₹23.69 cr, +12.27% YoY from ₹21.10 cr in H1 FY26 |
| EBITDA margin | 27.57% |
| Net profit | ₹16.79 cr, +12.38% YoY from ₹14.94 cr in H1 FY26 |
| Net profit margin | 19.54% |
| Revenue growth (existing facility) | ~10% YoY for H1 FY27, constrained by capacity |
| FY29 revenue projection | ₹300 cr, management reaffirmed earlier guidance |
| Existing facility capacity utilization | 128%, up from 124% previously |
| YEIDA facility total capex | ~₹184 cr |
| YEIDA capex incurred as of Sep 30, 2026 | ~₹110 cr, funded via IPO proceeds and internal accruals; IPO proceeds fully deployed |
| Capital work in progress | ₹88 cr on H1 FY27 balance sheet (per an analyst's math) |
| HDFC loan arranged for YEIDA | ₹60 cr |
| Current asset turnover | ~1x |
| YEIDA facility plot size | 21,250 sq m, facility built on half the plot |